文献速递肿瘤 PET/CT

前列腺癌PET示踪剂在健康组织中的摄取变异性多中心分析

Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone.
PubMed 文献 · J Nucl Med · 2019-01-10

该多中心研究分析了232例前列腺癌PET/CT扫描,量化了68Ga-PSMA、18F-DCFPyL、18F-FCH和18F-FDHT在健康组织中的摄取变异性,并识别出稳定参考区域。结果显示68Ga-PSMA和18F-DCFPyL血池变异最低,18F-FCH和18F-FDHT肝脏变异最低,且不同SUV类型对变异性影响有限。

要点

  • 68Ga-PSMA和18F-DCFPyL血池变异最低,可作为参考区域。
  • 18F-FCH和18F-FDHT肝脏变异最低,可作为参考区域。
  • 不同SUV类型对摄取变异性影响有限。

核心结论

  • 健康组织摄取变异性低的区域可作为前列腺癌PET判读的参考区域。
  • 68Ga-PSMA和18F-DCFPyL的参考区域为血池,18F-FCH和18F-FDHT为肝脏。
  • 健康组织SUV参考范围可用于图像质量控制。

研究设计与样本

  • 多中心分析232例前列腺癌PET/CT扫描,包括87例68Ga-PSMA、50例18F-DCFPyL、68例18F-FCH和27例18F-FDHT。
  • 在血池、肺、肝、骨髓和肌肉中评估示踪剂摄取,使用SUVmax、SUVmean和SUVpeak。
  • 采用变异系数(COV%)分析患者间摄取变异性。

主要发现

  • 68Ga-PSMA血池变异最低(COV 19.9%),显著低于其他组织(COV 29.8%-35.2%,P=0.001-0.024)。
  • 18F-DCFPyL血池和肝脏变异最低(COV 14.4%和21.7%,P=0.001-0.003)。
  • 18F-FCH肝脏、血池和骨髓变异最低(COV 16.8%-24.2%,P=0.001-0.012)。
  • 18F-FDHT除肺外所有组织变异低(COV 14.6%-23.6%,P=0.001-0.040)。
  • 不同SUV类型对变异性影响有限(COV差异在3个百分点内)。

关键数值与推荐

  • 68Ga-PSMA血池COV为19.9%,其他组织COV为29.8%-35.2%(P=0.001-0.024)。
  • 18F-DCFPyL血池和肝脏COV分别为14.4%和21.7%(P=0.001-0.003)。
  • 18F-FCH肝脏、血池和骨髓COV为16.8%-24.2%(P=0.001-0.012)。
  • 18F-FDHT除肺外组织COV为14.6%-23.6%(P=0.001-0.040)。

临床怎么用

  • 对于68Ga-PSMA和18F-DCFPyL PET,可使用血池作为参考区域判读病变。
  • 对于18F-FCH和18F-FDHT PET,可使用肝脏作为参考区域判读病变。
  • 健康组织SUV参考范围(95th百分位数)可用于未来PET采集的图像质量控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PET is increasingly used for prostate cancer (PCa) diagnostics. Important PCa radiotracers include 68Ga-prostate-specific membrane antigen HBED-CC (68Ga-PSMA), 18F-DCFPyL, 18F-fluoromethylcholine (18F-FCH), and 18F-dihydrotestosterone (18F-FDHT). Knowledge on the variability of tracer uptake in healthy tissues is important for accurate PET interpretation, because malignancy is suspected only if the uptake of a lesion contrasts with its background. Therefore, the aim of this study was to quantify uptake variability of PCa tracers in healthy tissues and identify stable reference regions for PET interpretation. Methods: A total of 232 PCa PET/CT scans from multiple hospitals was analyzed, including 87 68Ga-PSMA scans, 50 18F-DCFPyL scans, 68 18F-FCH scans, and 27 18F-FDHT scans. Tracer uptake was assessed in the blood pool, lung, liver, bone marrow, and muscle using several SUVs (SUVmax, SUVmean, SUVpeak). Variability in uptake between patients was analyzed using the coefficient of variation (COV%). For all tracers, SUV reference ranges (95th percentiles) were calculated, which could be applicable as image-based quality control for future PET acquisitions. Results: For 68Ga-PSMA, the lowest uptake variability was observed in the blood pool (COV, 19.9%), which was significantly more stable than all other tissues (COV, 29.8%-35.2%; P = 0.001-0.024). For 18F-DCFPyL, the lowest variability was observed in the blood pool and liver (COV, 14.4% and 21.7%, respectively; P = 0.001-0.003). The least variable 18F-FCH uptake was observed in the liver, blood pool, and bone marrow (COV, 16.8%-24.2%; P = 0.001-0.012). For 18F-FDHT, low uptake variability was observed in all tissues, except the lung (COV, 14.6%-23.6%; P = 0.001-0.040). The different SUV types had limited effect on variability (COVs within 3 percentage points). Conclusion: In this multicenter analysis, healthy tissues with limited uptake variability were identified, which may serve as reference regions for PCa PET interpretation. These reference regions include the blood pool for 68Ga-PSMA and 18F-DCFPyL and the liver for 18F-FCH and 18F-FDHT. Healthy tissue SUV reference ranges are presented and applicable as image-based quality control.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jansen BHE, Kramer GM, Cysouw MCF, et al. Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. J Nucl Med. 2019. PMID: 30630941. doi:10.2967/jnumed.118.222505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。